Cutler Group’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-1,000
Closed -$3K 3662
2023
Q3
$3K Sell
1,000
-700
-41% -$3.93K ﹤0.01% 3057
2023
Q2
$8K Hold
1,700
﹤0.01% 2351
2023
Q1
$7K Sell
1,700
-1,321
-44% -$5.69K ﹤0.01% 2522
2022
Q4
$11K Sell
3,021
-800
-21% -$3.82K ﹤0.01% 2617
2022
Q3
$22K Hold
3,821
﹤0.01% 2534
2022
Q2
$13K Sell
3,821
-2,000
-34% -$7.1K ﹤0.01% 2998
2022
Q1
$19K Sell
5,821
-7,600
-57% -$30K ﹤0.01% 3090
2021
Q4
$39K Sell
13,421
-921
-6% -$3.23K ﹤0.01% 2592
2021
Q3
$57K Buy
14,342
+6,056
+73% +$27.6K ﹤0.01% 2402
2021
Q2
$42K Buy
8,286
+6,586
+387% +$27.9K ﹤0.01% 2632
2021
Q1
$7K Hold
1,700
﹤0.01% 4087
2020
Q4
$5K Sell
1,700
-2,027
-54% -$8.79K ﹤0.01% 3623
2020
Q3
$19K Buy
+3,727
New +$21.7K ﹤0.01% 2489

Other funds holding CAPR

Cutler Group's CAPR Position: Q4 2023 in Review

Cutler Group sold out of Capricor Therapeutics (CAPR) in Q4 2023, closing a stake of 1,000 shares — an estimated $3K sold.

Cutler Group first reported a position in CAPR in Q3 2020 and held it in 13 quarters. The position peaked at $57K in Q3 2021. 37 funds tracked by Wall St. Rank hold CAPR as of Q4 2023.

  • Cutler Group reported no remaining Capricor Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 1,000 Capricor Therapeutics shares in Q4 2023, an estimated $3K.
  • Cutler Group first reported a position in Capricor Therapeutics in Q3 2020 and held it in 13 quarters.
  • Cutler Group's Capricor Therapeutics position peaked at $57K in Q3 2021.
  • 37 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.